High clinical response rate of sézary syndrome to immunomodulatory therapies: Prognostic markers of response

Archives of Dermatology

Volumn 147, Issue 12, 2011, Pages 1410-1415

  Raphael, Brian A ^a   Shin, Daniel B ^a   Suchin, Karen R ^a   Morrissey, Kelly A ^a   Vittorio, Carmela C ^a   Kim, Ellen J ^a   Gardner, Jennifer M ^a   Evans, Katherine G ^a   Introcaso, Camille E ^a   Samimi, Sara S ^a   Gelfand, Joel M ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; PSORALEN; RETINOID;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CD4+ CD26- T LYMPHOCYTE; CD4+ CD7- T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SEZARY SYNDROME; SYSTEMIC THERAPY; T LYMPHOCYTE; TOTAL SKIN ELECTRON THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MONOCYTES; PHOTOPHERESIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84255193016     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.232     Document Type: Article

References (21)

1. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364-370.
2. Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous Tcell lymphoma. Biologics. 2008;2(4):717-724.
3. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798-812. (Pubitemid 40489380)
4. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol. 1996;35(6):946-957. (Pubitemid 26422119)
5. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood. 1996;88(7):2385-2409.
6. Girardi M, Heald PW,Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350(19):1978-1988. (Pubitemid 38580201)
7. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-442. (Pubitemid 351642616)
8. Olsen E, Vonderheid E, Pimpinelli N, et al. ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722. (Pubitemid 47443880)
9. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054-1060. (Pubitemid 34875609)
10. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009; 48(3):243-252.
11. Evans AV, Wood BP, Scarisbrick JJ, et al. Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response. Blood. 2001; 98(5):1298-1301.
12. Vonderheid EC, Pena J, Nowell P. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma. 2006;47(9):1841-1856. (Pubitemid 44649769)
13. Scarisbrick JJ, Taylor P, Holtick U, et al. Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008;158(4):659-678. (Pubitemid 351415723)
14. Vonderheid EC, Sobel EL, Nowell PC, Finan JB, Helfrich MK, Whipple DS. Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood. 1985;66(2):358-366. (Pubitemid 15007027)
15. Schechter GP, Sausville EA, Fischmann AB, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood. 1987;69(3):841-849. (Pubitemid 17057466)
16. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med. 1988;109(5):372-382.
17. Toro JR, Stoll HL Jr, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 1997;37 (1):58-67. (Pubitemid 27287694)
18. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol. 2005;153(1):118-124. (Pubitemid 41044537)
19. Lin JH, Kim EJ, Bansal A, et al. Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. Blood. 2008;112(6):2484- 2488.
20. Evans KG, Troxel AB, DeNardo BJ, Introcaso CE, Rook AH, Kim EJ. Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 2011; 64(4):682-689.
21. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J AmAcad Dermatol. 2000;43(2, pt 1):263-271. (Pubitemid 30626004)